Journal of Blood & Lymph

ISSN: 2165-7831

Open Access

Current Issue

Volume 11, Issue 7 (2021)

    Volume 11, Issue 8 (2021)

      Editorial Pages: 1 - 1

      Risk Features for Hodgkin lymphoma

      Abidugun Azi

      Lymphoma is a gathering of blood malignancies that create from lymphocytes (a kind of white blood cell).The name frequently alludes to simply the dangerous forms instead of every such cancer. Signs and indications might incorporate amplified lymph hubs, fever, soaking sweats, accidental weight reduction, tingling, and continually feeling tired.The augmented lymph hubs are generally effortless. The sweats are generally normal around evening time. The two primary classifications of lymphomas are the non-Hodgkin lymphoma (NHL)(90% of cases) and Hodgkin lymphoma (HL) (10%). The World Health Organization (WHO) incorporates two different classes as kinds of lymphoma – numerous myeloma and immunoproliferative sicknesses. Lymphomas and leukemias are a piece of the more extensive gathering of cancers of the hematopoietic and lymphoid tissues

      Editorial Pages: 1 - 1

      Vitamin B12 Deficiency Anemia is Pernicious Anemia,

      Bunkechukwu Mehemed

      Iron deficiency is an ailment where the blood is low in ordinary red platelets. Malevolent pallor is one reason for nutrient B-12 inadequacy sickliness. It's idea primarily to be brought about by an immune system measure that makes an individual unfit to deliver a substance in the stomach called inborn factor. This substance is expected to assimilate dietary nutrient B-12 in the small digestive system.

      Commentry Pages: 2 - 2

      A Brief Note on Paroxysmal Nocturnal Hemoglobinuria

      Bunkechukwu Mehemed

      Paroxysmal nighttime hemoglobinuria (PNH) is an uncommon, received, dangerous infirmity of the blood portrayed through annihilation of red platelets by utilizing the supplement device, a piece of the body's intrinsic resistant gadget. This harming procedure happens because of lack of the red platelet floor protein DAF, which for the most part represses such invulnerable responses. Since the supplement course assaults the dark red platelets in the veins of the circulatory framework, the red blood portable annihilation (hemolysis) is considered an intravascular hemolytic pallor

      Research Article Pages: 5 - 6

      Molecular Epidemiology of BCR-ABL Rearrangement Variants in Chronic Myeloid Leukemia and Acute Lymphocytic Leukemia from Major Institute of Pakista

      Hussain Ahmed Raza1, Muhammad Shariq Shaikh2, Muhmmad Hasan Hayat2, Hamayail Ansari1, Huzaifa Bin Rashid1, Tariq Moatter3 and Zeeshan Ansar Ahmed3

      In Pakistan the disease burden of Chronic Myeloid Leukemia (CML) and Acute Lymphoblastic Leukemia (ALL) is quite high, yet there is a lack of scientific evidence regarding the spectrum of BCR-ABL rearrangement variants in CML and ALL. Knowing about BCR-ABL rearrangement is important in determining the prognosis and treatment strategy of disease at the time of diagnosis. This study included a total of 685 patients, out of which there were 644 CML patients and 41 ALL patients, from October 2016-July 2019. From the CML group, 270 patients were reported to have the BCR-ABL1 transcript, from which 50% were males. Whereas in the ALL group, 35 patients were reported to have the BCR-ABL1 transcript out of which 65.7% were males. Proportions of BCR-ABL transcript type differed between the two groups, with b3a2 (63.3%) and b2a2 (34.8%) transcript types having the highest frequency in CML patients, whereas e1a2 (77.1%) and b3a2 (11.3%) transcript types were found to have the highest frequency in ALL patients. Our data shows transcript genotypes in CML and ALL patients in an Asian population, which may be useful to guide the clinical management and assess prognosis. Since the majority of our CML population had the b3a2 transcript, they have a better prognosis and treatment response.

      Commentary Pages: 0 - 3

      A System Biology Perspective to Overcoming the Challenges of JAK Inhibition Mon Therapy for Myeloproliferative Neoplasms: An Overview

      Alphonsus Ogbonna Ogbuabor1*, Peter Uwadiegwu Achukwu2, Silas Anayo Ufelle1,2, and Daniel Chukwuemeka Ogbuabor1,3

      The JAK-STAT pathway mediates signals that are involved in hematopoiesis. Aberrant JAK-STAT signaling has been identified in myeloproliferative neoplasm making the pathway a novel therapeutic target for myeloproliferative neoplasms through the application of JAK inhibitors. A major limitation to therapy with the current JAK inhibitors is a lack of selectivity which results in toxicity to patients. It is thought that increasing the selectivity of inhibitors will reduce toxicity observed with JAK inhibition therapy. System biology is a novel technology that holds great potentials for increasing the selectivity of JAK inhibitors. Its Application to drug designing can broaden the spectrum as well as repurpose the available JAK inhibitors for improved clinical outcome and possible cure for myeloproliferative neoplasms. This review presents an overview on the role of system biology in JAK inhibition therapy for myeloproliferative neoplasms.

    Relevant Topics

Google scholar citation report
Citations: 282

Journal of Blood & Lymph received 282 citations as per google scholar report

Journal of Blood & Lymph peer review process verified at publons

Indexed In

arrow_upward arrow_upward